For the treatment of RET fusion-positive NSCLC, chemotherapy is still the most commonly used treatment regimen, and the ORR of platinum-based [15] and pemetrexed [24] chemotherapy studies were 51% and 45%, respectively. This evidence concerns the gene RET and non-small cell lung carcinoma.